
|Videos|January 11, 2018
Examining Response Rates in MSI-H and NTRK Fusion GI Cancers
Author(s)Luis A. Diaz, M.D.
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Advertisement
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Finding these biomarkers in patients with GI cancers can be particularly important, as it can help choose a treatment plan that can have a dramatic response in this group of patients.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows
2
FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma
3
Expert insights into Biomarker-Driven Care and Emerging Targets in GI Cancer
4
Onvansertib Combo Improves Outcomes in First-Line RAS-Mutated mCRC
5



